Establishment Labs Holdings Inc (NASDAQ:ESTA) Director Nicholas Sheridan Lewin acquired 2,700 shares of the stock in a transaction dated Monday, August 19th. The shares were bought at an average price of $20.11 per share, with a total value of $54,297.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Establishment Labs stock traded down $0.69 during mid-day trading on Monday, reaching $20.00. The stock had a trading volume of 128,664 shares, compared to its average volume of 63,236. The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.10 and a current ratio of 3.94. Establishment Labs Holdings Inc has a fifty-two week low of $19.61 and a fifty-two week high of $30.70. The stock’s 50-day simple moving average is $22.82 and its 200-day simple moving average is $24.36. The firm has a market capitalization of $410.00 million and a PE ratio of -17.86.
Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.08. Establishment Labs had a negative return on equity of 60.43% and a negative net margin of 38.63%. The firm had revenue of $21.68 million during the quarter, compared to analysts’ expectations of $20.10 million. On average, research analysts forecast that Establishment Labs Holdings Inc will post -1.97 earnings per share for the current fiscal year.
A number of equities analysts have recently issued reports on the company. Stephens assumed coverage on Establishment Labs in a research report on Thursday, June 6th. They set an “overweight” rating and a $37.00 price objective for the company. ValuEngine raised Establishment Labs from a “hold” rating to a “buy” rating in a research note on Monday, July 29th. Wells Fargo & Co set a $29.00 target price on Establishment Labs and gave the stock a “buy” rating in a research note on Friday, July 12th. BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of Establishment Labs in a research note on Thursday, May 16th. Finally, Zacks Investment Research cut Establishment Labs from a “hold” rating to a “sell” rating in a research note on Friday. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $35.33.
Establishment Labs Company Profile
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.
Featured Story: Stochastic Momentum Index (SMI)
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.